Abeona Therapeutics (ABEO) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub lowered shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a strong sell rating in a report issued on Friday, BidAskClub reports.

Several other analysts have also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $30.00 price objective on shares of Abeona Therapeutics in a report on Thursday, February 21st. ValuEngine cut Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, February 5th. Maxim Group reissued a buy rating on shares of Abeona Therapeutics in a report on Wednesday, May 1st. Cantor Fitzgerald set a $29.00 price objective on Abeona Therapeutics and gave the stock a buy rating in a report on Tuesday, March 19th. Finally, Zacks Investment Research raised Abeona Therapeutics from a sell rating to a hold rating in a report on Wednesday, February 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $26.43.

Shares of NASDAQ:ABEO opened at $7.44 on Friday. The stock has a market cap of $365.77 million, a price-to-earnings ratio of -6.25 and a beta of 1.92. Abeona Therapeutics has a 1-year low of $6.26 and a 1-year high of $21.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 4.37.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.06. The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.66 million. Abeona Therapeutics had a negative return on equity of 45.58% and a negative net margin of 960.91%. As a group, sell-side analysts expect that Abeona Therapeutics will post -1.5 EPS for the current year.

In related news, Director Stefano Buono bought 70,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was bought at an average cost of $7.80 per share, for a total transaction of $546,000.00. Following the transaction, the director now owns 20,980 shares of the company’s stock, valued at $163,644. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stephen B. Howell bought 4,000 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were bought at an average price of $7.77 per share, with a total value of $31,080.00. Following the completion of the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $46,620. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Abeona Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock valued at $28,418,000 after purchasing an additional 35,610 shares during the period. Dimensional Fund Advisors LP acquired a new position in Abeona Therapeutics in the third quarter valued at $933,000. Man Group plc acquired a new position in Abeona Therapeutics in the third quarter valued at $267,000. Teachers Advisors LLC increased its stake in Abeona Therapeutics by 75.6% in the third quarter. Teachers Advisors LLC now owns 98,192 shares of the biopharmaceutical company’s stock valued at $1,257,000 after purchasing an additional 42,261 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Abeona Therapeutics by 7.6% in the third quarter. Vanguard Group Inc. now owns 1,539,008 shares of the biopharmaceutical company’s stock valued at $19,699,000 after acquiring an additional 108,333 shares in the last quarter. Institutional investors own 67.53% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Story: What are the qualifications of a portfolio manager?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Westlake Chemical  Upgraded at ValuEngine
Westlake Chemical Upgraded at ValuEngine
Morgan Stanley Reiterates “$84.00” Price Target for Exxon Mobil
Morgan Stanley Reiterates “$84.00” Price Target for Exxon Mobil
Tenax Therapeutics  versus Its Rivals Critical Contrast
Tenax Therapeutics versus Its Rivals Critical Contrast
Steelcase  Stock Rating Lowered by Zacks Investment Research
Steelcase Stock Rating Lowered by Zacks Investment Research
Consumer Edge Lowers Kellogg  to Underweight
Consumer Edge Lowers Kellogg to Underweight
Grana y Montero SAA  Stock Rating Upgraded by Zacks Investment Research
Grana y Montero SAA Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.